Key result
Small-molecule Slack inhibitors emerge in recent patent applications for treating childhood epilepsies.
Why the study?
Quinidine inhibits Slack channels linked to malignant migrating partial seizures of infancy, but its clinical utility is limited by poor selectivity, safety, and pharmacokinetic profiles.
This review highlights recent patent applications for small-molecule Slack channel inhibitors as potential therapeutics for childhood epilepsies.
Slack channels merit targeting in MMPSI; leaves open development of selective inhibitors superior to quinidine.
gain of function mutations have been linked to malignant migrating partial seizures of infancy. Quinidine is an anti-arrhythmic drug that functions as a moderately potent inhibitor of Slack channels; however, quinidine use is limited by its poor selectivity, safety and pharmacokinetic profile. Slack channels represent an interesting target for developing novel therapeutics for the treatment of malignant migrating partial seizures of infancy and other childhood epilepsies; thus, ongoing efforts are directed toward the discovery of small-molecules that inhibit Slack currents. This review summarizes patent applications published in 2020-2021 that describe the discovery of novel small-molecule Slack inhibitors.
No takes yet. Share an insight, caveat, or question.
Qunies et al. (2022) conducted a review in Childhood epilepsies (malignant migrating partial seizures of infancy). Small-molecule Slack inhibitors was evaluated. This review summarizes patent applications published in 2020-2021 describing the discovery of novel small-molecule Slack inhibitors for the treatment of childhood epilepsies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: